Rash as a surrogate marker for efficacy of epidermal growth factor receptor inhibitors in lung cancer.

Roman Perez-Soler

Research output: Contribution to journalArticlepeer-review

106 Scopus citations


Rash and other cutaneous adverse events are class-effect toxicities seen with therapeutic agents such as the small-molecule tyrosine kinase inhibitors erlotinib and gefitinib and monoclonal antibodies cetuximab and panitumumab, targeting the epidermal growth factor receptor (EGFR) in the treatment of cancer. Rash has been reported in approximately two thirds of patients treated with these agents in phase II/III clinical trials in different tumor types. The rash that occurs with EGFR-targeted agents is generally mild to moderate; severe (grade 3/4) rash is rare (< 15% in non-small-cell lung carcinoma trials). In a number of clinical trials, the association of the incidence and severity of rash with response and survival after treatment with erlotinib or gefitinib has been analyzed. Although the significance of the association is yet to be determined, in most studies, a positive correlation between rash and clinical outcomes with EGFR-targeted therapy has been demonstrated. Therefore, the potential of using rash as a surrogate marker for efficacy of EGFR inhibitors in lung cancer therapy exists and needs to be further explored. This article provides a review of the data evaluating the association between rash and treatment outcomes and summarizes the current knowledge regarding the significance of this association. Understanding the biology/etiology of the rash resulting from EGFR inhibitors and assessing its correlation with treatment outcomes in large, prospective trials will help define the role of rash as a surrogate marker for efficacy of EGFR-targeted therapy.

Original languageEnglish (US)
Pages (from-to)S7-14
JournalClinical lung cancer
Volume8 Suppl 1
StatePublished - Dec 2006
Externally publishedYes

ASJC Scopus subject areas

  • Oncology
  • Pulmonary and Respiratory Medicine
  • Cancer Research


Dive into the research topics of 'Rash as a surrogate marker for efficacy of epidermal growth factor receptor inhibitors in lung cancer.'. Together they form a unique fingerprint.

Cite this